Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


13.11.2017

3 Am J Gastroenterol
1 Clin Res Hepatol Gastroenterol
2 Dig Dis Sci
1 Eur J Gastroenterol Hepatol
1 Gastroenterology
12 J Crohns Colitis
1 JAMA
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Gastroenterol

  1. CLICK B, Anderson AM, Koutroubakis IE, Rivers CR, et al
    Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype.
    Am J Gastroenterol. 2017 Nov 7. doi: 10.1038/ajg.2017.
    PubMed     Text format     Abstract available

  2. BERNSTEIN CN, Kornbluth A
    Yes, We Are Still Talking about Cylosporin vs. Infliximab in Steroid Resistant Acute Severe Ulcerative Colitis.
    Am J Gastroenterol. 2017;112:1719-1721.
    PubMed     Text format     Abstract available

  3. ABE K, Nakamura N, Isono A, Toyota H, et al
    Inflammatory Bowel Disease in an Elderly Woman After Nivolumab Administration.
    Am J Gastroenterol. 2017;112:1636.
    PubMed     Text format    


    Clin Res Hepatol Gastroenterol

  4. HANAEI S, Sadr M, Rezaei A, Shahkarami S, et al
    Association of NLRP3 single nucleotide polymorphisms with ulcerative colitis: A case-control study.
    Clin Res Hepatol Gastroenterol. 2017 Nov 1. pii: S2210-7401(17)30212.
    PubMed     Text format     Abstract available


    Dig Dis Sci

  5. FISCHER M, Campbell SC, Calley CSJ, Helper DJ, et al
    Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
    Dig Dis Sci. 2017;62:3131-3137.
    PubMed     Text format     Abstract available

  6. HAR-NOY O, Katz L, Avni T, Battat R, et al
    Chromoendoscopy, Narrow-Band Imaging or White Light Endoscopy for Neoplasia Detection in Inflammatory Bowel Diseases.
    Dig Dis Sci. 2017;62:2982-2990.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  7. WILLEMZE RA, Bakker T, Pippias M, Ponsioen CY, et al
    beta-Blocker use is associated with a higher relapse risk of inflammatory bowel disease: a Dutch retrospective case-control study.
    Eur J Gastroenterol Hepatol. 2017 Nov 3. doi: 10.1097/MEG.0000000000001016.
    PubMed     Text format     Abstract available


    Gastroenterology

  8. DULAI PS, Singh S, Ohno-Machado L, Sandborn WJ, et al
    Population Health Management for Inflammatory Bowel Disease.
    Gastroenterology. 2017 Nov 6. pii: S0016-5085(17)36337.
    PubMed     Text format     Abstract available


    J Crohns Colitis

  9. KOLHO KL, Pessia A, Jaakkola T, de Vos WM, et al
    Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:321-334.
    PubMed     Text format     Abstract available

  10. DECOCK A, Van Assche G, Vermeire S, Wuyts W, et al
    Sarcoidosis-Like Lesions: Another Paradoxical Reaction to Anti-TNF Therapy?
    J Crohns Colitis. 2017;11:378-383.
    PubMed     Text format     Abstract available

  11. COLLINS M, Sarter H, Gower-Rousseau C, Koriche D, et al
    Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence.
    J Crohns Colitis. 2017;11:281-288.
    PubMed     Text format     Abstract available

  12. SEVERS M, Oldenburg B, van Bodegraven AA, Siersema PD, et al
    The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:289-296.
    PubMed     Text format     Abstract available

  13. JAUREGUI-AMEZAGA A, Geerits A, Das Y, Lemmens B, et al
    A Simplified Geboes Score for Ulcerative Colitis.
    J Crohns Colitis. 2017;11:305-313.
    PubMed     Text format     Abstract available

  14. CESARINI M, Collins GS, Ronnblom A, Santos A, et al
    Predicting the Individual Risk of Acute Severe Colitis at Diagnosis.
    J Crohns Colitis. 2017;11:335-341.
    PubMed     Text format     Abstract available

  15. SEVERS M, Mangen MJ, van der Valk ME, Fidder HH, et al
    Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:342-352.
    PubMed     Text format     Abstract available

  16. DIBLEY L, Bager P, Czuber-Dochan W, Farrell D, et al
    Identification of Research Priorities for Inflammatory Bowel Disease Nursing in Europe: a Nurses-European Crohn's and Colitis Organisation Delphi Survey.
    J Crohns Colitis. 2017;11:353-359.
    PubMed     Text format     Abstract available

  17. MOURAD FH, Barada KA, Saade NE
    Impairment of Small Intestinal Function in Ulcerative Colitis: Role of Enteric Innervation.
    J Crohns Colitis. 2017;11:369-377.
    PubMed     Text format     Abstract available

  18. BUER LC, Moum BA, Cvancarova M, Warren DJ, et al
    Switching from Remicade(R) to Remsima(R) is well Tolerated and Feasible: A Prospective, Open-label Study.
    J Crohns Colitis. 2017;11:297-304.
    PubMed     Text format     Abstract available

  19. FIORINO G, Morin M, Bonovas S, Bonifacio C, et al
    Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome.
    J Crohns Colitis. 2017;11:274-280.
    PubMed     Text format     Abstract available

  20. KEANE TJ, Dziki J, Sobieski E, Smoulder A, et al
    Restoring Mucosal Barrier Function and Modifying Macrophage Phenotype with an Extracellular Matrix Hydrogel: Potential Therapy for Ulcerative Colitis.
    J Crohns Colitis. 2017;11:360-368.
    PubMed     Text format     Abstract available


    JAMA

  21. LEMAITRE M, Kirchgesner J, Rudnichi A, Carrat F, et al
    Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
    JAMA. 2017;318:1679-1686.
    PubMed     Text format     Abstract available


    PLoS One

  22. FUKUDA T, Naganuma M, Sugimoto S, Nanki K, et al
    The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry.
    PLoS One. 2017;12:e0187737.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: